G Attard
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
STAMPEDE Investigators, Parikh O, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N, James N, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Brown J, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Ann Oncol 2020; 31:442.
31.01.2020Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
31.01.2020Ann Oncol 2020; 31:442
STAMPEDE Investigators, Parikh O, O'Sullivan J M, Omlin Aurelius, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N N, James N D, Parmar M K B, Sydes M R, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J S, Simms M, Brown J, Russell J M, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C D, Attard G, Amos C L, Hoyle A, Ingleby F C, Ali A, Dearnaley D P, Douis H, Gilbert D, Ritchie A W S, Parker C C, Millman R, Matheson D, Mason M D, Malik Z, MacNair A, Langley R E, Jones R J, Gillessen S, Clarke N W
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2019; 30:e3.
01.12.2019Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
01.12.2019Ann Oncol 2019; 30:e3
Tombal B, Padhani A R, Olmos D, Oh W K, Nilsson S, Mastris K, Logothetis C J, Lecouvet F E, James N D, Hussain M, Parker C, Rubin M A, Tannock I F, Sweeney C J, Suzuki H, Sternberg C N, Small E J, Shore N D, Sella A, Scher H I, Schalken J A, Heidenreich A, Gleave M E, Smith M R, Sartor O, Nelson P S, Halabi S, Fizazi K, Efstathiou E, de Bono J S, Attard G, Omlin Aurelius, Soule H R, Akaza H, Fanti S, Eeles R A, Drake C G, De Santis M, Davis I D, Daugaard G, Chinnaiyan A M, Beltran H, Beer T M, Gillessen Sommer Silke
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
James N, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Brown J, Parikh O, Protheroe A, Rudman S, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Srihari N, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 2019
27.09.2019Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
27.09.2019Ann Oncol 2019
James N D, O'Sullivan J M, Omlin Aurelius, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Brown J, Parikh O, Protheroe A, Rudman S, Parmar M K B, Sydes M R, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J S, Simms M, Srihari N N, Russell J M, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C D, Attard G, Amos C L, Hoyle A, Ingleby F C, Ali A, Dearnaley D P, Douis H, Gilbert D, Ritchie A W S, Parker C C, Millman R, Matheson D, Mason M D, Malik Z, MacNair A, Langley R E, Jones R J, Gillessen S, Clarke N W
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
STAMPEDE Investigators, Protheroe A, Peedell C, Parikh O, O'Sullivan J, Nikapota A, Lester J, McLaren D, Hughes R, Gilbert D, Gibbs S, Rudman S, Shaffer R, Sheehan D, James N, Parmar M, Wagstaff J, Varughese M, Tsang D, Tolan S, Sundar S, Strebel R, Srihari N, Simms M, Gale J, Ford D, Evans L, Malik Z, Gillessen Sommer S, Cross W, Chowdhury S, Attard G, de Bono J, Dearnaley D, Clarke N, Mason M, Spears M, Jones R, Parker C, Ritchie A, Choudhury A, Chakraborti P, Capaldi L, Brock S, Birtle A, Gilson C, Amos C, Matheson D, Millman R, Russell J, Sydes M. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 2018; 29:1235-1248.
01.05.2018Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
01.05.2018Ann Oncol 2018; 29:1235-1248
STAMPEDE Investigators, Protheroe A, Peedell C, Parikh O, O'Sullivan J, Nikapota A, Lester J F, McLaren D, Hughes R, Gilbert D C, Gibbs S, Rudman S M, Shaffer R, Sheehan D, James N D, Parmar M K B, Wagstaff J, Varughese M, Tsang D, Tolan S, Sundar S, Strebel R, Srihari N, Simms M, Gale J, Ford D, Evans L, Malik Z I, Gillessen Sommer Silke, Cross W, Chowdhury S, Attard G, de Bono J S, Dearnaley D P, Clarke N W, Mason M D, Spears M R, Jones R, Parker C C, Ritchie A W S, Choudhury A, Chakraborti P, Capaldi L, Brock S, Birtle A, Gilson C, Amos C, Matheson D, Millman R, Russell J M, Sydes M R
Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer
Pezaro C, James N, Logothetis C, Morgans A, Parker C, Ryan C, Saad F, Sartor O, Small E, Sternberg C, Sweeney C, Tannock I, Tombal B, Hussain M, Higano C, Omlin A, Mastris K, Attard G, Beer T, Chi K, Chowdhury S, Davis I, Drake C, de Bono J, Efstathiou E, Gravis G, Gillessen Sommer S. Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer. Ann Oncol 2017; 28:1692-1694.
01.08.2017Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer
01.08.2017Ann Oncol 2017; 28:1692-1694
Pezaro C J, James N, Logothetis C J, Morgans A, Parker C, Ryan C J, Saad F, Sartor O, Small E J, Sternberg C N, Sweeney C J, Tannock I, Tombal B, Hussain M, Higano C S, Omlin Aurelius, Mastris K, Attard G, Beer T M, Chi K N, Chowdhury S, Davis I D, Drake C G, de Bono J S, Efstathiou E, Gravis G, Gillessen Sommer Silke
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2016
02.05.2016Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
02.05.2016Ann Oncol 2016
Tombal B, Padhani A R, Olmos D, Oh W K, Nilsson S, Mastris K, Logothetis C J, Lecouvet F E, James N D, Hussain M, Parker C, Rubin M A, Tannock I F, Sweeney C J, Suzuki H, Sternberg C N, Small E J, Shore N D, Sella A, Scher H I, Schalken J A, Heidenreich A, Gleave M E, Smith M R, Sartor O, Nelson P S, Halabi S, Fizazi K, Efstathiou E, de Bono J S, Attard G, Omlin Aurelius, Soule H R, Akaza H, Fanti S, Eeles R A, Drake C G, De Santis M, Davis I D, Daugaard G, Chinnaiyan A M, Beltran H, Beer T M, Gillessen Sommer Silke
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Tombal B, Padhani A, Olmos D, Oh W, Nilsson S, Mastris K, Logothetis C, Lecouvet F, James N, Hussain M, Parker C, Rubin M, Tannock I, Sweeney C, Suzuki H, Sternberg C, Small E, Shore N, Sella A, Scher H, Schalken J, Heidenreich A, Gleave M, Smith M, Sartor O, Nelson P, Halabi S, Fizazi K, Efstathiou E, de Bono J, Attard G, Omlin A, Soule H, Akaza H, Fanti S, Eeles R, Drake C, De Santis M, Davis I, Daugaard G, Chinnaiyan A, Beltran H, Beer T, Gillessen Sommer S. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015; 26:1589-604.
03.06.2015Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
03.06.2015Ann Oncol 2015; 26:1589-604
Tombal B, Padhani A R, Olmos D, Oh W K, Nilsson S, Mastris K, Logothetis C J, Lecouvet F E, James N D, Hussain M, Parker C, Rubin M A, Tannock I F, Sweeney C J, Suzuki H, Sternberg C N, Small E J, Shore N D, Sella A, Scher H I, Schalken J A, Heidenreich A, Gleave M E, Smith M R, Sartor O, Nelson P S, Halabi S, Fizazi K, Efstathiou E, de Bono J S, Attard G, Omlin Aurelius, Soule H R, Akaza H, Fanti S, Eeles R A, Drake C G, De Santis M, Davis I D, Daugaard G, Chinnaiyan A M, Beltran H, Beer T M, Gillessen Sommer Silke
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer
Pezaro C, Sohaib A, de Bono J, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin A, Tunariu N. Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. Clin Radiol 2014
30.12.2014Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer
30.12.2014Clin Radiol 2014
Pezaro C, Sohaib A, de Bono J S, Dearnaley D, Parker C, Lorente D, Bianchini D, Attard G, Mukherji D, Perez-Lopez R, Omlin Aurelius, Tunariu N
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
Lorente D, de Bono J, Gillessen Sommer S, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin A, Attard G. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 2014
14.10.2014Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
14.10.2014Br J Cancer 2014
Lorente D, de Bono J, Gillessen Sommer Silke, Dearnaley D, Parker C, Tunariu N, Zafeirou Z, Altavilla A, Mateo J, Perez R, Pezaro C, Ferraldeschi R, Omlin Aurelius, Attard G
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
Leibowitz-Amit R, de Bono J, Tannock I, Sridhar S, Knox J, Attard G, Seah J, Vera-Badillo F, Keizman D, Atenafu E, Pezaro C, Omlin A, Templeton A, Joshua A. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol 2014; 25:657-62.
23.01.2014Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
23.01.2014Ann Oncol 2014; 25:657-62
Leibowitz-Amit R, de Bono J S, Tannock I F, Sridhar S S, Knox J J, Attard G, Seah J-A, Vera-Badillo F, Keizman D, Atenafu E G, Pezaro C, Omlin Aurelius, Templeton Arnoud, Joshua A M
Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'. Br J Cancer 2013; 110:267-8.
03.12.2013Reply: 'Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer'
03.12.2013Br J Cancer 2013; 110:267-8
Omlin Aurelius, de Bono J S, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C J, Attard G
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
Bianchini D, de Bono J, Scher H, Attard G, Rathkopf D, Buchbinder A, Zivi A, Riisnaes R, Miranda S, Figueiredo I, Crespo M, Mukherji D, Ferraldeschi R, Lorente D, Pezaro C, Omlin A, Danila D. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer 2013; 109:2579-86.
29.10.2013First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
29.10.2013Br J Cancer 2013; 109:2579-86
Bianchini D, de Bono J, Scher H I, Attard G, Rathkopf D E, Buchbinder A, Zivi A, Riisnaes R, Miranda S, Figueiredo I, Crespo M, Mukherji D, Ferraldeschi R, Lorente D, Pezaro C, Omlin Aurelius, Danila D C
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
Bianchini D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin A, Rodriguez-Vida A, Lorente D, de Bono J. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2013; 50:78-84.
25.09.2013Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
25.09.2013Eur J Cancer 2013; 50:78-84
Bianchini D, Chowdhury S, Attard G, Zivi A, Ferraldeschi R, Pezaro C, Omlin Aurelius, Rodriguez-Vida A, Lorente D, de Bono J S
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
Omlin A, de Bono J, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C, Attard G. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. Br J Cancer 2013; 109:1079-84.
08.08.2013Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
08.08.2013Br J Cancer 2013; 109:1079-84
Omlin Aurelius, de Bono J S, Van As N, Parker C, Dearnaley D, Sandhu S, Ferraldeschi R, Bianchini D, Mukherji D, Lorente D, Zaidi S, Pezaro C J, Attard G
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
Pezaro C, de Bono J, Olmos D, Reid A, Seed G, Bianchini D, Omlin A, Cassidy A, Tunariu N, Mukherji D, Attard G. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer 2013; 109:325-31.
27.06.2013Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
27.06.2013Br J Cancer 2013; 109:325-31
Pezaro C, de Bono J S, Olmos D, Reid A H M, Seed G, Bianchini D, Omlin Aurelius, Cassidy A M, Tunariu N, Mukherji D, Attard G
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
Sandhu S, Assiotis I, Olmos D, Yap T, Fong P, Tunariu N, Koh D, Molife L, Kaye S, Lord C, Ashworth A, Fenwick K, Campbell J, Omlin A, Hylands L, Miranda S, Barber L, Riisnaes R, Reid A, Attard G, Chen L, Kozarewa I, Gevensleben H, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol 2013; 24:1416-8.
22.03.2013Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
22.03.2013Ann Oncol 2013; 24:1416-8
Sandhu S K, Assiotis I, Olmos D, Yap T A, Fong P, Tunariu N, Koh D, Molife L R, Kaye S, Lord C J, Ashworth A, Fenwick K, Campbell J, Omlin Aurelius, Hylands L, Miranda S, Barber L J, Riisnaes R, Reid A H, Attard G, Chen L, Kozarewa I, Gevensleben H, de Bono J